Effect of tamoxifen on endometrial histology, hormone receptors, and cervical cytology: A prospective study with follow-up

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 3, 2007, Pages 284-293

  Leslie, Kimberly K ^a   Walter, Sarah A ^b   Torkko, Kathleen ^b   Stephens, Janet K ^c   Thompson, Chesney ^b   Singh, Meenakshi ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Exempla Saint Joseph Hospital   (United States)

Author keywords

Endometrial carcinoma; Estrogen receptor; Progesterone receptor isoforms A and B; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ECHOGRAPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; METAPLASIA; PAPANICOLAOU TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; UTERINE CERVIX CYTOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID; TAMOXIFEN; VAGINAL SMEARS;

EID: 34548213273     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000213147.54901.12     Document Type: Article

References (33)

1. Seoud M, Shamseddine A, Khalil A, et al. Tamoxifen and endometrial pathologies: a prospective study. Gynecol Oncol. 1999;75:15-19.
2. Mourits MJ, Ten Hoor KA, van der Zee AG, et al. The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. J Clin Pathol. 2002;55:514-519.
3. Larsen P, Kronenberg H, Melmed S, et al. Williams Textbook of Endocrinology. 10th ed. Philadelphia: WB Saunders; 2003.
4. Senkus-Konefka E, Konefka T, Jassem J. The effects of tamoxifen on the female genital tract. Cancer Treat Rev. 2004;30:291-301.
5. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
6. Deligdisch L. Hormonal pathology of the endometrium. Mod Pathol. 2000;13:285-294.
7. Gill BL, Simpson JF, Somlo G, et al. Effects of tamoxifen on the cytology of the uterine cervix in breast cancer patients. Diagn Cytopathol. 1998;19:417-422.
8. Karck U, Kommoss F. Does tamoxifen change oestrogen and progesterone receptor expression in the endometrium and breast? Eur J Cancer. 2000;36(suppl 4):S45-S46.
9. Trégon ML, Blumel JE, Tarin JJ, et al. The early response of the postmenopausal endometrium to tamoxifen: expression of estrogen receptors, progesterone receptors, and Ki-67 antigen. Menopause. 2003;10:154-159.
10. Schwartz LB, Krey L, Demopoulos R, et al. Alterations in steroid hormone receptors in the tamoxifen-treated endometrium. Am J Obstet Gynecol. 1997;176:129-137.
11. Arnett-Mansfield RL, DeFazio A, Mote PA, et al. Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium. J Clin Endocrinol Metab. 2004;89:1429-1442.
12. Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci U S A. 2000;97:1032-1037.
13. Clarke CL, Zaino RJ, Feil PD, et al. Monoclonal antibodies to human progesterone receptor: characterization by biochemical and immunohistochemical techniques. Endocrinology. 1987;121:1123-1132.
14. Sakaguchi H, Fujimoto J, Hong BL, et al. Drastic decrease of progesterone receptor form B but not A mRNA reflects poor patient prognosis in endometrial cancers. Gynecol Oncol. 2004;93:394-399.
15. Mote PA, Johnston JF, Manninen T, et al. Detection of progesterone receptor forms A and B by immunohistochemical analysis. J Clin Pathol. 2001;54:624-630.
16. Isaksson E, Wang H, Sahlin L, et al. Effects of long-term HRT and tamoxifen on the expression of progesterone receptors A and B in breast tissue from surgically postmenopausal cynomolgus macaques. Breast Cancer Res Treat. 2003;79:233-239.
17. Dai D, Litman ES, Schonteich E, et al. Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. J Steroid Biochem Mol Biol. 2003;87:123-131.
18. Dai D, Wolf DM, Litman ES, et al. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res. 2002;62:881-886.
19. Davies S, Dai D, Feldman I, et al. Identification of a novel mechanism of NF-kappaB inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: induction of A20 and ABIN-2. Gynecol Oncol. 2004;94:463-470.
20. Davies S, Dai D, Wolf DM, et al. Immunomodulatory and transcriptional effects of progesterone through progesterone A and B receptors in Hec50co poorly differentiated endometrial cancer cells. J Soc Gynecol Invest. 2004;11:494-499.
21. Leslie KK, Stein M-P, Kumar NS, et al. Progesterone receptor isoform identification and sub-cellular localization in endometrial cancer. Gynecol Oncol. 2005;96:32-41.
22. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet. 1994;343:1318-1321.
23. Granberg S, Wikland M, Karlsson B, et al. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol. 1991;164:47-52.
24. Goldstein SR, Nachtigall M, Snyder JR, et al. Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol. 1990;163:119-123.
25. Hulka CA, Hall DA. Endometrial abnormalities associated with tamoxifen therapy for breast cancer: sonographic and pathologic correlation. AJR Am J Roentgenol. 1993;160:809-812.
26. Zaino RJ. Interpretation of Endometrial Biopsies and Curettings: Biopsy Interpretation Series. Philadelphia: Lippincott-Raven; 1996.
27. Deligdisch L, Kalir T, Cohen CJ, et al. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol. 2000;78:181-186.
28. Cohen I, Azaria R, Bernheim J, et al. Risk factors of endometrial polyps resected from postmenopausal patients with breast carcinoma treated with tamoxifen. Cancer. 2001;92:1151-1155.
29. Al-Azemi M, Labib NS, Omu AE. Endometrial changes in postmenopausal breast cancer patients on tamoxifen. Int J Gynaecol Obstet. 2002;79:47-49.
30. Kommoss F, Karck U, Prompeler H, et al. Steroid receptor expression in endometria from women treated with tamoxifen. Gynecol Oncol. 1998;70:188-191.
31. Leslie KK, Kumar NS, Richer J, et al. Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells. Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation. Ann N Y Acad Sci. 1997;828:17-26.
32. Kumar NS, Richer J, Owen G, et al. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res. 1998;58:1860-1865.
33. Lahti E, Vuopala S, Kauppila A, et al. Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen. Gynecol Oncol. 1994;55:410-414.